MEDIPOST (Korea: 078160) announced it has received FDA agreement to conduct a single pivotal Phase 3 study for CARTISTEM in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE